KLK3与TMPRSS2在前列腺癌根治术分子淋巴结分期中的价值
该前瞻性研究评估了6个候选基因标记在111例接受根治性前列腺切除术及扩大盆腔淋巴结清扫的患者中检测盆腔淋巴结转移及预测生化复发无生存的能力。结果显示KLK3与组织病理学一致性最高(96%),KLK3和TMPRSS2的分子淋巴结状态是bRFS的独立预测因子,且仅分子阳性(molN1/pN0)患者的中位bRFS显著缩短。
要点
- KLK3与组织病理学淋巴结分期一致性最高(96%)。
- KLK3和TMPRSS2分子淋巴结状态是bRFS独立预测因子。
- 仅分子阳性患者中位bRFS显著缩短。
核心结论
- KLK3在检测淋巴结转移方面与组织病理学一致性最高,KLK3和TMPRSS2对bRFS的预后价值优于组织病理学淋巴结状态及其他转录本,建议采用KLK3/TMPRSS2联合面板进行分子淋巴结分析。
研究设计与样本
- 前瞻性研究,纳入111例接受根治性前列腺切除术及扩大盆腔淋巴结清扫且未接受新辅助治疗的患者(中危32例,29%;高危79例,71%),共检测2411枚淋巴结。
主要发现
- 组织病理学在28例(25%)患者中检出69枚淋巴结转移。
- KLK2和KLK3诊断性能最佳,将所有pN1患者正确分类为分子淋巴结阳性(molN1/pN1)。
- KLK3在淋巴结水平一致性最佳(96%)。
- KLK2、KLK3、KLK4、PSMA、TMPRSS2和TRPM8分别将27例(24%)、32例(29%)、29例(26%)、8例(7%)、13例(12%)和23例(21%)pN0患者重新分类为淋巴结阳性(pN0/molN1)。
- 多因素Cox回归分析显示,基于KLK3(HR 4.0,p=0.04)和TMPRSS2(HR 5.1,p=0.02)的分子淋巴结状态(molN1 vs. molN0)是bRFS的独立预测因子。
临床怎么用
- 对于接受根治性前列腺切除术的患者,可考虑采用KLK3/TMPRSS2联合面板进行分子淋巴结分析,以提高微小转移灶的检出并改善生化复发风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lymph-node (LN) metastasis in prostate cancer (PC) is a main risk factor for tumor recurrence after radical prostatectomy (RP). Molecular analysis facilitates detection of small-volume LN metastases with higher sensitivity than histopathology. We aimed to prospectively evaluate six candidate gene markers for detection of pelvic LN metastases and to determine their ability to predict biochemical recurrence-free survival (bRFS) in patients treated with RP. METHODS: The expression of kallikrein 2, 3, and 4 (KLK2, KLK3, and KLK4), prostate-specific membrane antigen (PSMA), transmembrane serine protease 2 (TMPRSS2) and transient receptor potential cation channel subfamily M member 8 (TRPM8) was assessed using qPCR. We analyzed LNs from 111 patients (intermediate PC, n = 32 (29%); high-risk PC, n = 79 (71%)) who underwent RP and extended pelvic lymph-node dissection without neoadjuvant treatment. RESULTS: Overall, 2411 LNs were examined by molecular and histopathologic examination. Histopathology detected 69 LN metastases in 28 (25%) patients. KLK2 and KLK3 diagnostically performed best and classified all pN1-patients correctly as molecular node-positive (molN1/pN1). The concordance on LN level was best for KLK3 (96%). KLK2, KLK3, KLK4, PSMA, TMPRSS2, and TRPM8 reclassified 27 (24%), 32 (29%), 29 (26%), 8 (7%), 13 (12%), and 23 (21%) pN0-patients, respectively, as node-positive (pN0/molN1). On multivariable cox regression analysis molecular LN status (molN1 vs. molN0) using KLK3 (HR 4.0, p = 0.04) and TMPRSS2 (HR 5.1, p = 0.02) were independent predictors of bRFS. Median bRFS was shorter in patients with only molecular positive LNs (molN1/pN0) for KLK3 (24 months, p = 0.001) and for TMPRSS2 (12 months, p < 0.001) compared to patients with negative nodes (molN0/pN0) (median bRFS not reached). CONCLUSIONS: For diagnostic purposes, KLK3 showed highest concordance with histopathology for detection of LN metastases in PC patients undergoing RP. For prognostic purposes, KLK3 and TMPRSS2 expression were superior to histopathologic LN status and other transcripts tested for molecular LN status. We suggest a combined KLK3/TMPRSS2 panel as a valuable diagnostic and prognostic tool for molecular LN analysis.
引用
- Lunger L, Retz M, Bandur M, et al. KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy. Prostate Cancer Prostatic Dis. 2020. PMID: 32978525. doi:10.1038/s41391-020-00283-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。